AbCellera Biologics Inc. logo

AbCellera Biologics Inc. (ABCL)

Market Closed
10 Jul, 20:00
NASDAQ (NGS) NASDAQ (NGS)
$
4. 25
+0.03
+0.71%
$
1.13B Market Cap
- P/E Ratio
0% Div Yield
4,255,100 Volume
-0.47 Eps
$ 4.22
Previous Close
Day Range
4.14 4.33
Year Range
1.89 4.33
Want to track ABCL and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 32 days
AbCellera Biologics Inc. (ABCL) Reports Q3 Loss, Misses Revenue Estimates

AbCellera Biologics Inc. (ABCL) Reports Q3 Loss, Misses Revenue Estimates

AbCellera Biologics Inc. (ABCL) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.10 per share a year ago.

Zacks | 8 months ago
AbCellera to Present at Upcoming Investor Conferences in November 2024

AbCellera to Present at Upcoming Investor Conferences in November 2024

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present at Upcoming Investor Conferences in November 2024.

Businesswire | 8 months ago
AbCellera: A Platform To Pipeline Transition

AbCellera: A Platform To Pipeline Transition

AbCellera is shifting its focus from a platform biotech company to its internal drug pipeline. The company's lead asset, ABCL575, comes with a variety of risks, but in our opinion, has a value of a little over $1B and is derisked based on comparable therapeutics. AbCellera is on track to submit ABCL575 for clinical trials in Q22025, helping the market reset its valuation on the company closer to the value of the lead asset.

Seekingalpha | 8 months ago
AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024

AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024.

Businesswire | 9 months ago
AbCellera: A Waiting Game With High Uncertainty

AbCellera: A Waiting Game With High Uncertainty

AbCellera's Q2 2024 revenue declined by 27% year-over-year to $7.3 million. The company's net loss widened to $36.9 million due to increased R&D expenses. AbCellera's cash and marketable securities totaled $697.6 million, with total liquidity exceeding $900 million.

Seekingalpha | 10 months ago
AbCellera Biologics Inc. (ABCL) Reports Q2 Loss, Misses Revenue Estimates

AbCellera Biologics Inc. (ABCL) Reports Q2 Loss, Misses Revenue Estimates

AbCellera Biologics Inc. (ABCL) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.11 per share a year ago.

Zacks | 11 months ago
5 Penny Stocks With 250% Upside in 1 Year According to Wall Street

5 Penny Stocks With 250% Upside in 1 Year According to Wall Street

Penny stocks represent an interesting investment opportunity.

247wallst | 11 months ago
Billionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio?

Billionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio?

The Baker brothers acquired millions of shares of AbCellera Biologics and Fate Therapeutics during the first months of 2024. AbCellera Biologics is a drug discovery business with a hand in more than a dozen experimental drugs in clinical-stage development.

Fool | 11 months ago
AbCellera Biologics (ABCL) Upgraded to Buy: Here's What You Should Know

AbCellera Biologics (ABCL) Upgraded to Buy: Here's What You Should Know

AbCellera Biologics (ABCL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks | 1 year ago
AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024

AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024.

Businesswire | 1 year ago
Down 57%, Is AbCellera Biologics a Buy on the Dip?

Down 57%, Is AbCellera Biologics a Buy on the Dip?

AbCellera Biologics is a biotechnology company built to discover new antibodies for other drugmakers. The stock has fallen more than 90% from its all-time high and by 57% from a peak it set last summer.

Fool | 1 year ago